Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

EVAX

Evaxion Biotech A/S ADR

Jun 25 • 04:00PM ET

2.81

Dollar change +0.12
Percentage change 4.46	%

Healthcare • Biotechnology • Denmark • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.55	Insider Own	-	Shs Outstand	3.79M	Perf Week	13.77%
Market Cap	14.67M	Forward P/E	-	EPS next Y	-0.77	Insider Trans	-	Shs Float	-	Perf Month	-27.58%
Income	-14.69M	PEG	-	EPS next Q	-0.39	Inst Own	7.31%	Short Float	-	Perf Quarter	-9.35%
Sales	0.12M	P/S	122.23	EPS this Y	91.65%	Inst Trans	-50.17%	Short Ratio	0.91	Perf Half Y	-59.20%
Book/sh	0.50	P/B	5.63	EPS next Y	-13.79%	ROA	-68.12%	Short Interest	0.04M	Perf Year	-77.15%
Cash/sh	2.25	P/C	1.25	EPS next 5Y	-	ROE	-320.15%	52W Range	2.26 - 13.82	Perf YTD	-59.02%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-18.88%	ROI	-259.79%	52W High	-79.67%	Beta	-0.28
Dividend TTM	-	Quick Ratio	1.18	Sales past 5Y	0.00%	Gross Margin	-	52W Low	24.34%	ATR (14)	0.31
Dividend Ex-Date	-	Current Ratio	1.18	EPS Y/Y TTM	42.99%	Oper. Margin	-16217.70%	RSI (14)	38.00	Volatility	9.31% 10.24%
Employees	49	Debt/Eq	4.18	Sales Y/Y TTM	-	Profit Margin	-11803.92%	Recom	1.00	Target Price	9.67
Option/Short	No / Yes	LT Debt/Eq	3.99	EPS Q/Q	110.51%	Payout	-	Rel Volume	0.19	Prev Close	2.69
Sales Surprise	37.84%	EPS Surprise	102.74%	Sales Q/Q	-	Earnings	May 28 BMO	Avg Volume	47.00K	Price	2.81
SMA20	-14.82%	SMA50	-24.01%	SMA200	-50.79%	Trades		Volume	9,016	Change	4.46%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-24	Upgrade	Ladenburg Thalmann	Neutral → Buy	$8
Feb-12-24	Initiated	H.C. Wainwright	Buy	$14

Jun-17-24 08:44AM	Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal (GlobeNewswire) -20.32%
Jun-13-24 09:55AM	Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jun-03-24 08:00AM	Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024 (GlobeNewswire)
May-28-24 02:52PM	EVAX Stock Earnings: Evaxion Biotech Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -5.20%
08:21AM	Evaxion Announces Business Update and First Quarter 2024 Financial Results (GlobeNewswire)
05:00PM	Loading…
May-23-24 05:00PM	Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024 (GlobeNewswire)
May-10-24 05:00PM	Evaxion Receives Nasdaq Notification (GlobeNewswire)
May-07-24 09:15AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE)
Apr-17-24 08:00AM	Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01 (GlobeNewswire)
Apr-03-24 11:26AM	Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data (Zacks) -7.22%
08:57AM	Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-02-24 07:00AM	Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection (GlobeNewswire) +20.12%
Mar-27-24 07:30AM	Evaxion Announces Business Update and Full Year 2023 Financial Results (GlobeNewswire)
Mar-19-24 07:30AM	Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology Platform (GlobeNewswire)
Feb-29-24 07:30AM	Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations (GlobeNewswire)
07:30AM	Loading…
Feb-20-24 07:30AM	Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD (GlobeNewswire)
Feb-07-24 08:30AM	Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Feb-06-24 08:30AM	Evaxion Announces Closing of $15 Million Public Offering (GlobeNewswire) +5.88%
Feb-01-24 09:20AM	Evaxion Biotech Announces Pricing of $15 Million Public Offering (GlobeNewswire) +17.05%
Jan-24-24 08:30AM	Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets (GlobeNewswire) +113.43%
Jan-22-24 04:30PM	Evaxion Announces Completion of ADS Ratio Change (GlobeNewswire) -45.36% +36.29%
Jan-08-24 08:30AM	Evaxion Announces Plan to Implement ADS Ratio Change (GlobeNewswire)
Dec-21-23 04:30PM	Evaxion Biotech Announces Closing of Private Placement (GlobeNewswire)
Dec-19-23 04:15PM	Evaxion Announces Business Update and Third Quarter 2023 Financial Results (GlobeNewswire) +6.91%
09:25AM	Evaxion Biotech Announces Private Placement Financing (GlobeNewswire)
Nov-28-23 08:27AM	Evaxion to Unveil Potentially Groundbreaking AI-Immunology Precision Cancer Vaccine Concept (GlobeNewswire)
Nov-15-23 08:00AM	Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy (GlobeNewswire)
Nov-06-23 10:12AM	Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak (GlobeNewswire)
Oct-31-23 11:15AM	Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01 (GlobeNewswire) +19.79%
Oct-26-23 08:30AM	New and Exciting Clinical Data on Evaxion's AI-Immunology -Based Personalized Cancer Vaccines to be Presented (GlobeNewswire) +20.57%
08:30AM	Loading…
Oct-05-23 08:30AM	Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire)
Sep-21-23 01:23PM	Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab (Zacks) +10.29%
Sep-20-23 08:26AM	Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea (GlobeNewswire) +41.67%
Sep-18-23 08:23AM	Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company (GlobeNewswire) -20.48%
Sep-11-23 08:17AM	Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development (GlobeNewswire) +14.63%
Aug-29-23 08:30AM	Evaxion announces Executive Management Changes to strengthen the AI-strategy (GlobeNewswire)
Aug-23-23 09:19AM	Evaxion Biotech A/S (NASDAQ:EVAX) Q2 2023 Earnings Call Transcript (Insider Monkey)
12:11AM	Q2 2023 Evaxion Biotech A/S Earnings Call (Thomson Reuters StreetEvents)
Aug-18-23 11:57AM	Evaxion Announces Business Update and Second Quarter 2023 Financial Results (GlobeNewswire) -8.00%
Aug-01-23 07:00AM	Evaxion announces financing commitments totaling up to USD 20 million with Negma Group (GlobeNewswire)
Jul-31-23 07:00AM	Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus (GlobeNewswire)
Jun-05-23 11:50AM	Why Are Evaxion Biotech Shares Trading Higher Today (Benzinga)
Jun-03-23 05:00PM	Evaxions AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial (GlobeNewswire)
Jun-01-23 06:53AM	Analysts Expect Breakeven For Evaxion Biotech A/S (NASDAQ:EVAX) Before Long (Simply Wall St.)
May-31-23 08:30AM	Evaxion Announces Business Update and First Quarter 2023 Financial Results (GlobeNewswire)
May-25-23 05:00PM	Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines (GlobeNewswire)
05:00PM	Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01 (GlobeNewswire)
May-16-23 05:47AM	Evaxion to host R&D Day on May 25, 2023 (GlobeNewswire)
Apr-27-23 07:00AM	Fourth quarter and full year 2022 financial results and business update (GlobeNewswire)
Apr-18-23 08:00AM	Evaxion announces promising clinical data for DNA-based personalized cancer immunotherapy EVX-02: Phase 1/2a trial met both primary and secondary endpoints (GlobeNewswire) -10.92%
Apr-13-23 09:44AM	Evaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platform (GlobeNewswire) +8.04%
Mar-28-23 07:46AM	Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients (GlobeNewswire) -12.40%
Mar-23-23 07:55AM	Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients (GlobeNewswire) -8.66%
Mar-14-23 04:30PM	Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR) (GlobeNewswire)
Feb-08-23 10:47AM	Evaxion Biotech, Pantherna Reveals Encouraging Data From mRNA-Based Cancer Vaccine (Benzinga)
06:30AM	Evaxion and Pantherna announce promising preclinical mRNA vaccine data (GlobeNewswire)
Jan-19-23 08:45AM	Evaxion receives FDA fast-track designation for personalized cancer immunotherapy (GlobeNewswire) +6.25%
Jan-03-23 08:14AM	Evaxion's stock soars after getting FDA approval for mid-stage cancer trial (MarketWatch)
07:30AM	Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01 (GlobeNewswire)
Dec-15-22 07:48AM	Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023 (GlobeNewswire)
Dec-06-22 08:18AM	Evaxion, ExpreS2ion Ink Research Pact For Cytomegalovirus Vaccine Candidate (Benzinga)
02:00AM	Evaxion and ExpreS²ion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidate (GlobeNewswire)
Nov-17-22 11:03AM	Evaxion Biotech Highlights Promising Data From Personalized Cancer Immunotherapy (Benzinga)
06:59AM	Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02 (GlobeNewswire)
Nov-14-22 07:13AM	Evaxion Announces Third Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Nov-10-22 04:10AM	Evaxion CEO comments on strategic focus (GlobeNewswire) +6.42%
Oct-11-22 11:54AM	10 Best Immunotherapy Stocks To Buy Now (Insider Monkey)
Oct-05-22 08:32AM	Evaxion welcomes Per Norlén as new CEO. (GlobeNewswire)
Sep-22-22 10:50AM	Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study (Zacks)
Sep-21-22 05:45AM	Important Milestone Reached for Evaxion Biotechs EVX-01 Personalized Cancer Therapy (GlobeNewswire) +22.63%
Sep-06-22 07:02AM	Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School (GlobeNewswire)
Aug-10-22 07:00AM	Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Aug-02-22 07:00AM	Evaxion Biotech A/S Announces Executive Management Changes (GlobeNewswire)
Jul-29-22 05:46PM	Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10 (GlobeNewswire)
Jun-30-22 07:00AM	Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target (GlobeNewswire)
Jun-23-22 12:10PM	Evaxion Biotech To Test EVX-03 DNA Vaccine For Non-Small Cell Lung Cancer (Benzinga) +5.11%
07:30AM	Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer (GlobeNewswire)
Jun-08-22 09:55AM	Bears are Losing Control Over Evaxion Biotech AS Sponsored ADR (EVAX), Here's Why It's a 'Buy' Now (Zacks) -9.79%
Jun-07-22 08:05AM	Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital (GlobeNewswire) +10.23%
May-11-22 07:30AM	Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -15.11%
May-10-22 07:30AM	Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02 (GlobeNewswire) -5.86%
Apr-29-22 12:16PM	Evaxion Biotech to Host Q1 2022 Corporate Update Conference Call & Webcast on May 11 (GlobeNewswire) -7.89%
Apr-26-22 08:45AM	Evaxion to Utilize Personalis ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma (Business Wire)
Apr-06-22 07:30AM	Evaxion Biotech Hosting Key Opinion Leader Webinar on Metastatic Melanoma and Personalized Cancer Immunotherapies (GlobeNewswire)
Mar-22-22 06:30AM	Evaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-14-22 07:00AM	Evaxion Biotech Strengthens Management Team with Two Senior Appointments (GlobeNewswire)
Mar-07-22 07:30AM	Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02 (GlobeNewswire)
Jan-26-22 07:30AM	Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck (GlobeNewswire) -9.30%
Jan-25-22 10:00AM	Evaxion Biotech AS Sponsored ADR (EVAX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Jan-21-22 02:30AM	Nasdaqs European Markets Delivered Record Year in 2021 (GlobeNewswire)
Jan-18-22 08:00AM	Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma (GlobeNewswire)
Dec-29-21 08:44AM	Do Options Traders Know Something About Evaxion (EVAX) Stock We Don't? (Zacks)
Nov-09-21 05:00PM	Evaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
06:30AM	Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-21 06:00AM	Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering (GlobeNewswire) -44.64%
Nov-04-21 07:05AM	24 Stocks Moving in Thursday's Pre-Market Session (Benzinga) +95.08%
Nov-01-21 08:17AM	Is Evaxion Biotech A/S (NASDAQ:EVAX) Popular Amongst Insiders? (Simply Wall St.)
Oct-26-21 07:49AM	Evaxion Biotech Announces Filing of Registration Statement in the U.S for Proposed Follow-on Public Offering to Raise Additional Capital (GlobeNewswire) -13.02%
Oct-25-21 05:30AM	Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma (GlobeNewswire) +9.17%
Oct-14-21 07:30AM	Evaxion Biotech Wins Frost & Sullivan 2021 Enabling Technology Leadership Award (GlobeNewswire) -5.31%

Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen Moller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EVAX

Evaxion Biotech A/S ADR

Upgrade your FINVIZ experience